ProCE Banner Activity

CE / CME

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

Video

Get up to date on the latest approaches using molecular testing in lung and thyroid cancers to guide treatment.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

ABPath MOC: maximum of 1.00 Lifelong Learning point

Released: April 10, 2023

Expiration: April 09, 2024

Share

Faculty

Saad A. Khan

Saad A. Khan, MD

Leader, Endocrine Cancer Research Group
Assistant Professor
Stanford University and Stanford Cancer Institute
Stanford, California

Sandip P. Patel

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group

Lilly

Partners

American Society for Clinical Pathology

ProCE Banner

Partnered with the American Society for Clinical Pathology.

Target Audience

This program is intended for medical oncologists, pathologists, endocrinologists, surgeons, interventional radiologists, nurses, pharmacists, and other healthcare professionals who care for patients with lung or thyroid cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung or thyroid cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Formulate strategies for integrating TRK and RET inhibitors into practice that include patient discussions, adverse event monitoring and management, and methods to enroll qualified patients on clinical trials
  • Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy

  • Manage treatment-related symptoms associated with the treatment of RET-altered or NTRK fusion–positive cancer

  • Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Saad A. Khan, MD

Leader, Endocrine Cancer Research Group
Assistant Professor
Stanford University and Stanford Cancer Institute
Stanford, California

Saad A. Khan, MD: consultant/advisor/speaker: Eisai, EMD Serono, Foundation Medicine, Roche Pakistan.

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Sandip P. Patel, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Genentech, Illumina, Merck, Pfizer, Rakuten, Tempus; researcher: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Iovance, Merck, Pfizer, Roche/Genentech, SQZ Biotechnologies.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 10, 2023, through April 09, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

 

 

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-090-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Learners will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 Lifelong Learning point in the American Board of Pathology's Maintenance of Certification (MOC) Program. Learners will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

For ABIM and ABPath MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM and AP Path records.